Cerebrolysin® is a neuropeptide preparation manufactured in fully controlled biotechnological process which stimulates neurotrophic regulation in the central nervous system.
Cerebrolysin® is used worldwide for treatment of ischemic and hemorrhagic stroke, traumatic brain injuries, different forms of dementia (vascular dementia, Alzheimer’s disease), cognitive disorders and for the prevention of cognitive decline after brain injuries.
Patients with either acute or degenerative neurological diseases benefit from the neuro-protective and neuro-regenerative properties of Cerebrolysin®.
The recommended dosage range of Cerebrolysin® is between 10 and 50 ml per day. It is recommended that the administration is done by infusion with an infusion duration of 15 minutes. For lower doses, Cerebrolysin® can be injected intramuscularly for doses of up to 5 ml and intravenously for doses up to 10 ml, in both cases without dilution.
Learn more: www.cerebrolysin.com